Tweet
Here's the patent kythera purchased the rights to. It states the the application will be topical, although no mention has been made about the delivery, besides this.
-
-
I don't know if you have ever seen this doc, so I share : http://files.shareholder.com/downloa...5BFA2E/KYTHERA
Page 6 and nextComment
-
Thank you my friend. I will look at these.
I asked because earlier in this very long thread I read that the preventative treatment may be released in conjunction with bimatoprost and a wounding protocol for regrowth. I don't know if that was correct or not. I'm on a slow connection so it would take about five minutes to page back.
I have abnormal scarring so I would like to know if wounding would due more harm than good to me, were it ever to become viable.
We need a collection of all the available primary documents surrounding these new treatments so folks can look through them all in one place. I see people referencing "the articles" but they are linked sporadically. Maybe I'll collect them up.Comment
-
Does anyone know why they are so vague when talking about the novel delivery method? It's patent protected right?Comment
-
I know that it can be converted into a topical 100%, because they have already (for the last 2 years) been testing 5 different GPR44 Blockers (one of which is Setipriprant) on explanted human hairs. Obviously a pill cannot be digested by a hair follicle.How do you 100% know anything about this?
Again, you are misrepresenting the truth, they said it would be "Oral dosing (improved compliance)" i.e people will find it easier to take the drug orally, leading to more sales etc. If it is just as effective orally as it is topically, then why not? If not, I wouldn't mind a topical formulation. The point is, both are possible.and in their shareholders presentation they clearly say it will be an oral drug
For anyone interested, a couple of years ago I created a thread with all the information I could find and my opinion.
Yes, this is all just basic science, and noone is saying it is a cure. There a no major side effects, headaches drowsiness etc are "side-effects" seen in almost every trial and some people think that something as trivial as a vitamin pill can give you those side effects...
The positives far way out the negatives, by leaps and bounds.Comment
-
I only mention these side effects because the percentages were very high, the incidence of such effects is very high with other antihistamines, and there is a withdrawal effect from these drugs that is not talked about even by many doctors. There are always low percentages of people that report headaches and drowsiness, but not at these percentages. If that's too hard to understand I don't know how else to say it. Talk to anyone who has taken zyrtec. I too hope that the side effects will be outweighed by the positives. Just don't get your hopes too high.
Also, Kythera purchased cotsarellis' patents, but that doesn't mean they will follow those patents. From their shareholders presentation its pretty obvious they plan to develop and test this as a pill. Is it possible to make it a topical? who knows, probably. Either way the side effect shouldn't vary much.Comment
-
This audio said nothing about delivery method. "the novel method of use" bought by kythera and provided by Upenn simply means the act of using setipriprant as a hair growth molecule. The molecule itself is being bought from actelion. Again, you are misunderstanding what people say and reading into things.
This is no big deal yet, they have no idea how it will work in vivo. Ramatroban keeps hair growing in vitro as well. Hopefully it wrks, but certainly no guarantees. Propecia maintains hair and grows a good amount in many people, so there's no way this gets released if it isn't as good, and other PGD2 receptor blockers have not panned out very well in unofficial trials.Comment
-
The side effects you're referring to were from a sample size of 20, so 2 people getting a fairly common human feeling = 10%. There was no placebo to compare to. Here is the excerpt from the study at http://www.ncbi.nlm.nih.gov/pubmed/24095247
"Setipiprant was well tolerated at the tested dose, with no apparent effects on clinical laboratory variables, vital signs, weight, ECG variables, or ECG morphology. In total, 10 of 20 subjects reported at least one adverse event (AE) during the study. Headache was the most frequently reported AE (in 25% of subjects), followed by flatulence (15%) and somnolence and fatigue (10%). Only 1 case of headache, 1 case of somnolence, and 2 cases of fatigue were judged to be related to study drug by the investigator.
No AEs of severe intensity and no serious AEs were reported during the study. One case of moderate headache (1 man, treatment A) and 2 cases of moderate fatigue (2 women, treatment B) were reported; all other AEs were rated to be of mild intensity by the investigator. All AEs resolved without sequelae. The AE incidence in men and women and between treatments was similar."Comment
-
Cool. Thanks for elucidating. I get bad sides from everything, and when I take zyrtec or claritin I get mild headaches and sometimes bad drowsiness. Might expect similar from this drug, a lot will probably tolerate it better, and some worse. I'm still most concerned about the withdrawal possibility after years of use, and would love to be able to talk to an expert about it. Sucks that kythera has no email.Comment
-
That's correct, and I wasn't trying to further my point by making that post. Just trying to share information in a helpful way. Anyway, they bought all the patents, which say topical. Who knows how they are going to administer it. I only doubt that it's oral, because they already tested it orally in healthy men and women.
Yes, also other PGD2 inhibitors have the same effect, but they chose this drug because of "specificity and safety."Comment
-
In any case, it will be interesting to see.
If replicel comes out with their product anytime near when these guys do, and replicel works, it's gonna be a much better option.Comment
-
Why is everyone on this forum so stuck on exclusive usage of treatments. I mean if Replicel and Setipripant both come out, you could use both of them.
That is the point of all the new possible treatments coming out (CB, Sm, Septipripant, Replicel, Histogen and even Pilofocus).
Replicel has the best safety profile. However I am betting that Histogen has the best effectivity.
In the end the more of them come out, more options we hive. I'm sure there will be people using all of them at once.Comment
Comment